The regulatory T cells induction by Epicutaneous immunotherapy is sustained and mediates long term protection from eosinophilic disorders in peanut sensitized mice

V. Dioszeghy
DBV Technologies
April 1, 2014
Clin Exp Allergy
https://pubmed.ncbi.nlm.nih.gov/24666588

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/24666588

Research summary

This study investigates the role of regulatory T cells (Tregs) in the efficacy of epicutaneous immunotherapy (EPIT) for peanut allergy. Using a BALB/c mouse model sensitized to peanut proteins, the researchers demonstrated that EPIT induces Foxp3⁺ Tregs that persist long after treatment cessation. Depletion of Tregs during EPIT abrogated its protective effects, while adoptive transfer of Tregs from EPIT-treated mice conferred protection against eosinophilic inflammation upon peanut challenge. These findings highlight the critical role of Tregs in mediating long-term tolerance induced by EPIT.

Key outcome of the study

EPIT induces durable Foxp3⁺ Tregs that are essential for long-term protection against eosinophilic disorders in peanut-sensitized mice.

Model

BALB/c mice sensitized to peanut proteins and treated with EPIT using Viaskin® patches. Tregs were depleted using anti-CD25 antibodies, and adoptive transfer experiments were conducted to assess Treg functionality.

TARGET:
FOXP3
Synonyms:
Forkhead box P3

Keywords

Food allergy, Immunotherapy, Regulatory T cells, Eosinophilic disorders, Peanut allergy

Technical specifications

BALB/c mouse model, Epicutaneous immunotherapy, Treg depletion, Adoptive Treg transfer

Related products

Catalogue product

No items found.

Customized product

Reporter KI mouse

Use a reporter mouse Knockin for in vivo monitoring of transcriptional promoter activity, protein localization, cell trafficking, etc.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe